Infliximab biosimilar (Celltrion)

英夫利西单抗生物类似药（Celltrion）

Report date: 2026/03/31 20:00:21

Base Information

Drug NameInfliximab biosimilar (Celltrion)
Drug Alias Nameinfliximab-dyybInfliximab BS-dyybInfliximabum-dyybRemsimaFlammegis +[14] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Biosimilar
Mechanisms of ActionAnti-Tumor necrosis factor α
TargetsTumor necrosis factor α
Therapy Area/IndicationsPlaque psoriasisPsoriasisCrohn Disease +[10] 
Global Approved IndicationsPlaque psoriasisPsoriasisCrohn Disease +[8] 
Approved Indications in ChinaArthritis, Rheumatoid
Original Approved Country/TerritoryEU
Original Approved Date2013/09/10
Country/TerritoryCzechiaBulgariaCanada +[31] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesCelltrion Inc
China Registration ClassN/A

Develop Information

Active CompaniesCelltrion Healthcare IncVcell Healthcare LtdCelltrion Healthcare Hungary Kft +[7] 
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisPsoriasisCrohn Disease +[10] 
Inactive IndicationsN/A

Other Information

ATC CodeL04AB02
Related LinksDrugBankKEGG